Company: APM
Filing Date: 2025-04-30
Form Type: 20-F
Source: 0001213900-25-037669
Chunk: 250

Company: Aptorum Group Ltd
Filing Date: 2025-04-30
Form: 20-F
Item: Item 19
Chunk 250
---
  Administrative management services (Note d)                                                                                                                                 
  - Libra Sciences Limited                                                                    $                 $                     9,615      $                    38,462  
  Healthcare services income                                                                                                                                                  
  - Aeneas Management Limited                                                                 $                 $                       961      $                     1,282  

Note a: On August 13, 2019, Aptorum Therapeutics
Limited (“ ATL”), a wholly owned subsidiary of the Company, entered into financing arrangements with Aeneas Group Limited,
a related party, and Jurchen Investment Corporation, the ultimate parent of the Group, allowing ATL to access up to a total $15million
in line of credit debt financing. Both line of credits have originally matured onAugust 12, 2022. ATL and Aeneas Group Limited has mutually
agreed to extend the line of credit arrangement further3years to August 12, 2025. The interest on the outstanding principal indebtedness
is at the rate of8% per annum. ATL may early repay, in whole or in part, the principal indebtedness and all interest accrued at any time
prior to the maturity date without the prior written consent of the lender and without payment of any premium or penalty. As of the issuance
date of this consolidated financial statements, the undrawn line of credit facility is $12million.

F-24

APTORUM GROUP LIMITED

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

(Stated in U. S. Dollars)

Note b: On November 17, 2021, ATL entered into
a loan agreement with Talem Medical Group Limited (the “ Borrower”). According to the loan agreement, ATL granted a loan of
up to AUD4,700,000for the Borrower for general working capital purposes of the Borrower and its subsidiaries. The loan is interest-bearing
at a rate of10% per annum and secured by the entire issued shares of Talem Medical Group (Australia) Pty Limited held by the Borrower.
The loan is initially matured 6 months from the date of the first drawdown. The maturity date was extended for 6 months to the first extended
maturity date, and further extended for another 6 months to the second extended maturity date. As of the date of the issuance of this
consolidated financial statements, there is no outstanding balance from the Borrower following a repayment in February 2023.

On January 13, 2022, ATL entered a line of credit